New Jersey

Patients With Epilepsy Navigate Murky Unregulated CBD Industry

In 2013, Tonya Taylor was suicidal because her epileptic seizures persisted despite taking a long list of medications. Then a fellow patient at a Denver neurologist’s office mentioned something that gave Taylor hope: a CBD oil called Charlotte’s Web. The person told her the oil helped people with uncontrolled epilepsy. However, the doctor would discuss …

Patients With Epilepsy Navigate Murky Unregulated CBD Industry Read More »

After initial failure, Intercept Pharma feels new data can get NASH drug approval

Two years after the stinging FDA rejection of its drug for the fatty liver disease NASH, Intercept Pharmaceuticals has more safety and efficacy data from a pivotal study that could support resubmission of a new drug application. The biotech said it will meet with the FDA later this month.

PMV’s ASCO data show signs of drugging ‘undruggable’ p53 protein across tumor types

PMV Pharmaceuticals has its first clinical data showing that its lead therapeutic candidate can hit p53, a tumor-suppressing protein long thought to be undruggable. After reporting the preliminary data during ASCO, PMV said it plans to continue Phase 1 study with the goal of advancing to Phase 2 early next year.

Becton Dickinson buys into pharmacy automation with $1.5B Parata acquisition

Becton Dickinson is getting into pharmacies with a more than $1.5 billion acquisition of Parata Systems, maker of robotics technologies that automate pharmacy tasks. The deal comes two months after BD completed the spinoff of its diabetes business as a separate, publicly traded company.

Aiming to make better mRNA vaccines, BioNTech strikes up alliance with Matinas

Oral delivery of messenger RNA is one of the capabilities of Matinas BioPharma’s technology. BioNTech will explore that feature among others under a new research alliance with Matinas, a clinical-stage biotech that also has an ongoing collaboration with Genentech.

Becton Dickinson spins off diabetes biz, enabling Embecta to embark on its own

The second quarter of 2022 kicked off with a new life sciences company joining the public markets, but not via an IPO or merger. Becton Dickinson on Friday completed the spinoff of its diabetes care business, Embecta, which now trades on the Nasdaq.

Princeton spinout ArrePath gets $20M to combine AI, imaging in antibiotics R&D

Anti-infective drug discovery startup ArrePath has launched with $20 million in seed funding to advance the development of molecules that use a dual mechanism to kill bacteria. The Princeton University spinout says its approach could overcome the drug resistance bacteria are developing to currently available products.

Qué hacer si perdiste tu tarjeta de vacunación contra la COVID-19

El certificado estadounidense no cabe en la billetera, así que no es de extrañar que lo hayas extraviado.

Qué hacer si perdiste tu tarjeta de vacunación contra la COVID-19

El certificado estadounidense no cabe en la billetera, así que no es de extrañar que lo hayas extraviado.

FDA rejects Merck chronic cough drug, asks for more info on efficacy

Merck is still at the front of the pack of companies developing new medicines to treat chronic cough, but the company was dealt a setback as the FDA turned down the pharma giant’s application and asked for additional efficacy data. No safety issues were raised, according to Merck.

Hospitales enfrentan más casos de covid en personas ya hospitalizadas, con menos personal

El 11 de enero, la Clínica Cleveland de Weston, en el sur de la Florida, estaba tratando a 80 pacientes con covid-19, 10 veces más que a fines diciembre. Casi la mitad fueron hospitalizados ​​por otras razones médicas. El aumento impulsado por la extremadamente infecciosa variante omicron abrumó al hospital de 206 camas: ahora tiene …

Hospitales enfrentan más casos de covid en personas ya hospitalizadas, con menos personal Read More »

Incidental Cases and Staff Shortages Make Covid’s Next Act Tough for Hospitals

The Cleveland Clinic in Weston, Florida, on Jan. 11 was treating 80 covid-19 patients — a tenfold increase since late December. Nearly half were admitted for other medical reasons. The surge driven by the extremely infectious omicron variant helped push the South Florida hospital with 206 licensed beds to 250 patients. The rise in cases …

Incidental Cases and Staff Shortages Make Covid’s Next Act Tough for Hospitals Read More »

J&J is latest big pharma, device company to call it splits with consumer health

Johnson & Johnson announced it plans to separate its consumer health products into a separate company, leaving the remaining business to focus on the more research-oriented pharmaceuticals and medical devices business segments. The announcement follows similar moves made by other large pharmaceutical and medical device companies.

Organon makes another women’s health move with deal for endometriosis-focused Forendo

Organon’s proposed acquisition of Forendo Pharma is the company’s third the company since spinning out of Merck in the summer. Clinical-stage Forendo is developing a new, potentially more targeted approach to treating endometriosis.

3 States Limit Nursing Home Profits in Bid to Improve Care

Nursing homes receive billions of taxpayers’ dollars every year to care for chronically ill frail elders, but until now, there was no guarantee that’s how the money would be spent. Massachusetts, New Jersey and New York are taking unprecedented steps to ensure they get what they pay for, after the devastating impact of covid-19 exposed …

3 States Limit Nursing Home Profits in Bid to Improve Care Read More »

Hackensack Meridian Health deploys Google Chrome OS devices, uses Cloud AI for screenings

The New Jersey-based health system initially partnered with Google in 2019. It has now migrated to Google Workspace, providing thousands of Chrome OS devices to remote workers, and is using Google Cloud AI capabilities to detect diseases like breast cancer and Covid-19.

Oyster Point dry eye drug is approved, but omission in label crimps financing plan

An Oyster Point Pharma drug for dry eye disease has won FDA approval, the first treatment for the condition that comes as a nasal spray. In addition to that drug approval, the FDA on Monday rejected two drugs, one from Omeros and the other from United Therapeutics.

Merck to buy Acceleron for $11.5B; cardio drug could cushion fall from Keytruda cliff

Merck is looking for products that diversify its portfolio beyond reliance on cancer drug Keytruda, and it sees a potential blockbuster cardiovascular drug from Acceleron Pharma as fitting the bill. The pharma giant is paying $11.5 billion to acquire the biotech, and executives say they’re still on the hunt for more deals.

Provider groups back Hackensack Meridian Health, Englewood Health’s appeal against merger delay

The American Hospital Association and Association of American Medical Colleges have filed an amicus brief in support of the New Jersey health systems that are appealing a court decision to delay their merger following a legal challenge from the FTC.

Racism, sexism and now fraud: Lawsuits pile up at New Jersey ‘AI’ firm

A previous investigation by MedCity News found that ElectrifAi was touting an improperly-developed algorithm during the earliest phase of the Covid-19 pandemic, with both the company and CEO defendants in an employment discrimination lawsuit. A year later, lawsuits are piling up as more former employees complain that the company and CEO lied about its AI …

Racism, sexism and now fraud: Lawsuits pile up at New Jersey ‘AI’ firm Read More »

Hackensack Meridian Health, Englewood Health appeal court decision to block merger  

The FTC sued to block the merger between the two New Jersey-based health systems and won a preliminary injunction earlier this month. But the providers believe that the merger would not raise prices or stifle competition — like the FTC alleges it would — and have filed an appeal.

Merck drug acquired in $1B deal approved to treat tumors sparked by rare disease

FDA approval of the Merck drug, belzutifan, covers treatment of tumors caused by von Hippel-Lindau disease, an inherited disorder associated with several types of cancer. Merck added the small molecule to its pipeline two years ago as part of a $1.2 billion acquisition.

Provention Bio drug for delaying type 1 diabetes hit with FDA delay of its own

Provention Bio needs to show the FDA that the drug substance produced from its contract manufacturer is comparable to the Eli Lilly-made drug substance that was evaluated in clinical trials. A larger study testing the prospective type 1 diabetes therapy teplizumab is ongoing and could provide the information the agency needs.

As Schools Spend Millions on Air Purifiers, Experts Warn of Overblown Claims and Harm to Children

Last summer, Global Plasma Solutions wanted to test whether the company’s air-purifying devices could kill covid-19 virus particles but could find only a lab using a chamber the size of a shoebox for its trials. In the company-funded study, the virus was blasted with 27,000 ions per cubic centimeter. This story also ran on CNN. …

As Schools Spend Millions on Air Purifiers, Experts Warn of Overblown Claims and Harm to Children Read More »

After Accident, Patient Crashes Into $700,000 Bill for Spine Surgery

Mark Gottlieb’s life changed in an instant when another driver crashed into his car, damaging four vertebrae in his upper spine and smashing six teeth. In the months following that January 2019 crash, Gottlieb got the teeth crowned and, for debilitating neck pain, tried injections, chiropractic care and physical therapy. The treatments were all covered …

After Accident, Patient Crashes Into $700,000 Bill for Spine Surgery Read More »

Merck’s Covid-19 drug R&D falls short twice in treating hospitalized patients

Merck is discontinuing work on one Covid-19 drug for treating hospitalized patients after the FDA said it needs more clinical data. Another Merck drug candidate is moving forward only in outpatient testing after independent clinical trial observers concluded the antiviral was unlikely to help those in the hospital.

Need Amid Plenty: Richest US Counties Are Overwhelmed by Surge in Child Hunger

Alexandra Sierra carried boxes of food to her kitchen counter, where her 7-year-old daughter, Rachell, stirred a pitcher of lemonade. This story also ran on USA Today and GateHouse Media. It can be republished for free. “Oh, my God, it smells so good!” Sierra, 39, said of the bounty she’d just picked up at a …

Need Amid Plenty: Richest US Counties Are Overwhelmed by Surge in Child Hunger Read More »

Short seller targets insurance startup Clover in scathing report

After a scathing report from short-seller Hindenburg claiming that Clover faced a False Claims Act investigation, the insurance startup’s stock plummeted. Clover went public last month after merging with a special-purpose acquisition company under billionaire investor Chamath Palihapitiya.  

Estados permiten contratar profesionales de salud extranjeros por la pandemia

Cuando los hospitales de todo el país luchan contra la nueva ola de la pandemia, no son camas ni ventiladores lo que escasean. Son las personas que cuidan de los enfermos. Pero existe mano de obra altamente calificada de médicos, enfermeras y otros trabajadores de salud, con formación en el extranjero, que no se aprovecha …

Estados permiten contratar profesionales de salud extranjeros por la pandemia Read More »

RWJBarnabas Health’s new program aims to identify social barriers to care without stigmatizing patients

The New Jersey-based health system’s culturally nuanced social determinants of health program will screen all patients for social and behavioral factors that impact their health, in the hopes of improving outcomes and encouraging appropriate use of healthcare services.

J&J to buy Momenta Pharmaceuticals for $6.5B

The drugmaker emphasized the full global rights it would acquire to Momenta’s lead asset, nipocalimab, which it is developing for several autoantibody-driven diseases and that in certain indications could have peak sales of more than $1 billion.